Free weight-loss visit planner. Bring your questions to your next appointment.

Growth hormone–releasing peptide

Compounded Sermorelin injection

A separate hormone-related topic. Understanding why sermorelin came up is the first question to bring to a clinician.

Browse guides
Illustrative Pulse+ Sermorelin injection bottle

Compounded medicines are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before marketing. Package images are illustrations. Read the FDA’s guidance.

Understand the distinction

Sermorelin stimulates the release of growth hormone. Its mechanism differs from GLP-1 treatments. Its historical US approval concerned a specific childhood growth disorder and does not establish a weight-management benefit.

Ask about the evidence

If sermorelin appears alongside weight-care options, ask the clinician to name the condition being assessed. Ask which evidence applies to people with that condition and which alternatives they would consider.

Clarify the product

Ask for the exact formulation, who prepares it and what follow-up would involve. A historical approval for one product does not confer approval on a newly compounded preparation.

Explore other injectables

Illustrative Pulse+ Tirzepatide injection packaging

Injection

Compounded Tirzepatide injection

Learn which product your clinician is discussing, why they are considering it and how they would review your progress.

Learn more
Illustrative Pulse+ Semaglutide injection packaging

Injection

Compounded Semaglutide injection

An ingredient may appear in several products. Start with the prescription name and the reason your clinician is considering it.

Learn more

Pulse+ visit planner

Prepare for your visit

Choose what matters to you. Take your questions to a conversation with your clinician.

What would you like to discuss?

Your selections stay in this tab until you close or reload the page.